t to pharmacological thromboprophylaxis,
the evidence is difﬁcult to generalize due to the limited
magnitude of effect among those systematic reviews
reporting a beneﬁt of routine thromboprophylaxis (number needed to treat 25.4-172.4 for the prevention of DVT),
lack of risk stratiﬁcation in most studies, and signiﬁcant
heterogeneity in the results. In addition to the uncertain
